We report a preterm male neonate with thrombosis of bilateral renal veins, infra-hepatic inferior vena cava, and superior sagittal sinus as well as left adrenal hemorrhage, which has been seldom reported in the literature. He was managed with appropriate antibiotics, enoxaparin, and supportive care which lead to resolution of thrombosis and normal renal function.
, Anmol Bhatia

6
IntroductIon N eonates are more predisposed to thrombosis than older children because of low levels of anticoagulants (antithrombin III, protein C and S) and fibrinolytic component (plasminogen). 1, 2 Risk factors for thrombosis in neonates include vascular catheters, birth asphyxia, dehydration, sepsis, acidosis, polycythemia, gestational diabetes mellitus (GDM), cyanotic heart diseases, inherited thrombophilia (deficiency of protein C, protein S, and antithrombin III), and acquired thrombophilia [placental transfer of antiphospholipid antibodies (APLA) and maternal autoimmune disorders. 1, 3, 4 Renal vein thrombosis (RVT) is the commonest noncatheter related thrombosis in neonates 2, 3 and can lead to longterm renal impairment. Cerebral sinovenous thrombosis (CSVT) though rare in neonates can lead to morbidities like seizures, cerebral palsy, and cognitive impairment.
We report a preterm neonate born to mother with GDM who presented in the early neonatal period with extensive thrombosis of bilateral renal veins, inferior vena cava (IVC) and superior sagittal sinus with adrenal hemorrhage. Treatment with enoxaparin leads to complete resolution of thrombosis.
cAse r e p o r t A 3-day-male neonate born to primigravida at 36 weeks of gestation (birth weight 2.5 kg) presented with hematuria and multiple seizures. Mother had a history of GDM and leaking per vaginum for 48 hours before delivery. He was admitted to a local hospital for 2 days and received intravenous antibiotics, fluids and vasoactive drugs, glucose infusion, and phenobarbitone.
Examination revealed normal vitals, pallor, pedal edema, encephalopathy, bimanually palpable and ballotable left flank mass, and dark colored urine.Investigations revealed blood glucose 98 mg%, hemoglobin 9.5 gm%, TLC 9600/mm 3 , platelet count 75,000/ mm 3 (Fig. 1C) .
He received intravenous vancomycin for 10 days. Vasoactive drugs and glucose infusion were stopped by day 2 of admission. Low molecular weight heparin (LMWH) was started (1.5 mg/kg BD subcutaneously). In next 3-5 days, there was improvement in coagulopathy, renal functions, hematuria, and encephalopathy. Magnetic resonance imaging (MRI) brain on day 15 of life revealed no CSVT. He was discharged on day 18 of life on LMWH. Serum homocysteine, ammonia, lactate, TMS and GCMS were normal. Maternal APLA workup, antinuclear antibodies, C3 and C4 were negative.
At 3 months of age, serum homocysteine was 6 µmol/L (normal: 4.2-12.8 µmol/L), protein C 48%, and protein S 78%; and negative anticardiolipin, anti-glycoprotein 1b antibodies, lupus anticoagulant, and factor V Leiden mutation. Ultrasonography showed resolution of thrombus and enoxaparin was stopped. At 6 months of age, he had normal growth and development, and renal functions. The etiology considered for extensive thrombosis was multifactorial including maternal GDM, prematurity, and sepsis. 
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superior sagittal sinus with adrenal hemorrhage is seldom reported in the literature. RVT accounts for 10-20% of venous thrombosis in neonates 3 and 45-65% of cases are associated with inherited thrombophilia. RVT is more common in males, preterm neonates, and large for gestational age babies. Majority of neonatal RVT are unilateral with left preponderance, and bilateral in about 25% of cases. 2 The thrombus may extend into IVC in 40-50% of cases and 15% may have adrenal hemorrhage.
3-6 Only 10-15% had classical triad palpable flank mass, hematuria, and renal failure. 1 The usual time of presentation is within the first 3 days of life, as in index case. Pohl et al. 7 reported a 3-week neonate with bilateral RVT and CSVT due to heterozygous factor V mutation with a complete resolution on heparin therapy. Klinge et al. 8 reported a neonate with bilateral RVT and CSVT due to heterozygous activated protein C resistance who was treated with selective thrombolysis.
The treatment of thrombosis in neonates depends on the extent of involvement and organ dysfunction and associated hemorrhage. [1] [2] [3] 9 Supportive treatment, anticoagulation with LMWH or UFH for 3-6 months, and rarely thrombolysis are suggestive treatment modalities. 3, 9 Anticoagulation has been shown to improve survival remarkably to 85-95% and prevents renal atrophy in 65-70% of cases. 9 Though the mortality in neonatal RVT is <5%, 3 the long term morbidity is significant including hypertension, tubular dysfunction, renal atrophy, and chronic kidney disease. 3 Poor prognosis is related to the extent of kidney damage, size (> 6 cm), and perfusion. 
